Alluvi, formerly BI 4744, offers a promising advance in obesity treatment. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates impressive results in https://bookmarkforest.com/story22054615/alluvi-a-detailed-dive-into-retatrutide-s-possibilities